cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.9700484
title: Cross-chest clips in child restraints: A crash testing study

description: <b>Objective:</b> Cross-chest clips are widely used in North American child restraints but are less common in other countries, partially due to concerns over anterior neck contacts in frontal crashes. They have recently been reported to be associated with lower odds of injury in real-world crashes, but there is a paucity of crash test performance information. This study aimed to compare the dynamic performance of a small child occupant in frontal crash tests with and without cross-chest clips in place. <b>Methods:</b> Frontal sled tests at 49 km/h were conducted to compare 2 cross-chest clip designs to nonuse of a chest clip. Tests using a P3/4 anthropomorphic test device (ATD) to represent the smallest occupant in a forward-facing child restraint were conducted with the chest clips in the recommended position and also in an incorrect lower position and with and without additional harness slack present. <b>Results:</b> Though contacts were observed between the chest clips and the base of the ATD’s neck, there was little difference observed in head excursion or ATD sensor loads in the presence of the chest clips. No detectable change in the neck forces or moments was detected at the time of the neck contacts. The position of the clips did not affect the results. Harness slack increased head excursion, as expected, but this effect did not differ between the tests with and without the clips. <b>Conclusions:</b> Cross-chest clips do not appear to greatly influence the dynamic performance of a forward-facing child restraint in a simulated frontal crash. Taken together with recent research suggesting a potential benefit in injury reduction from the clips in the real world, possibly due to maintaining the harness straps in place on a child’s shoulders, it may be appropriate to re-evaluate safety standards that prevent their use.
DOI: 10.6084/m9.figshare.9700541.v1
title: Morphological plasticity in brown-rot fungi: <i>Antrodia</i> is redefined to encompass both poroid and corticioid species

description: Most known brown rot–producing species of Polyporales belong to the so-called “Antrodia clade” that largely consists of poroid species. In this study, we use three genetic markers to revise <i>Antrodia</i> s. str., the core group of this clade. We show that a corticioid species with a smooth hymenophore, <i>Phlebia griseoflavescens</i>, belongs to <i>Antrodia</i> s. str. Accordingly, we revise the generic concept of <i>Antrodia</i> s. str. to accommodate this species and two recently described poroid taxa, <i>A. tenerifensis</i> and <i>A. multiformis</i>. In addition, we describe two new poroid species within <i>Antrodia</i> s. str., <i>A. latebrosa</i> from Africa and <i>A. peregrina</i> from East Asia, and provide new documentation for the Southeast Asian species <i>A. parvula</i> based on recent collections from the type location.
DOI: 10.6084/m9.figshare.9700466
title: Quantile Regression Code and Data

description: The SAS and R code and the accompanied data are related to the paper "The Advantages of Quantile Regression in Scientometrics"<br>
DOI: 10.6084/m9.figshare.9700538.v2
title: Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK

description: <b>Aim:</b> To evaluate the relative cost-effectiveness of using rivaroxaban vs apixaban for the initial treatment plus extended prevention of venous thromboembolism (VTE) in the UK. Extended prevention was assessed using a 10-mg rivaroxaban dose, as the 20-mg dose has already been evaluated. <b>Methods:</b> A Markov model compared the health outcomes and costs of treating VTE patient cohorts with either rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily for 6 months, then extended prevention with 10 mg once daily) or apixaban (10 mg twice daily for 1 week, followed by 5 mg twice daily for 6 months, then extended prevention with 2.5 mg twice daily) over a lifetime horizon. The model included an initial acute treatment and prevention phase (0–6 months) and an extended prevention phase (6–18 months). Efficacy and safety data were derived from two network meta-analyses. Reference treatment comparators were derived from the EINSTEIN-Pooled study and EINSTEIN-CHOICE trial. Healthcare costs and utility data were derived from published literature. <b>Results:</b> The rivaroxaban regimen was associated with increased quality-adjusted life years (QALYs) and slightly lower total costs compared with apixaban over a lifetime horizon. Deterministic and probabilistic sensitivity analyses demonstrated that rivaroxaban remained a cost-effective alternative to apixaban over a wide range of parameters. Incremental cost-effectiveness ratio estimates were below the £20,000 per QALY threshold in 74.1% of 2,000 model simulations. Scenario analyses further supported that rivaroxaban is a cost-effective alternative to apixaban. <b>Limitations:</b> Clinical and safety inputs were derived from network meta-analysis, which are subject to inherent limitations whereby small differences between study designs may severely impact efficacy and safety outcomes. Furthermore, these inputs were based on data from clinical trials, which may not reflect real-world data. <b>Conclusions:</b> Rivaroxaban was associated with a slightly lower total cost and increased QALYs compared with apixaban for VTE management in the UK over a lifetime horizon.
DOI: 10.6084/m9.figshare.9700538.v1
title: Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK

description: <b><i>Aim:</i></b> To evaluate the relative cost-effectiveness of using rivaroxaban versus apixaban for the initial treatment plus extended prevention of venous thromboembolism (VTE) in the UK. Extended prevention was assessed using a 10-mg rivaroxaban dose as the 20-mg dose has already been evaluated. <b><i>Methods:</i></b> A Markov model compared the health outcomes and costs of treating VTE patient cohorts with either rivaroxaban (15 mg twice daily for three weeks, followed by 20 mg once daily for six months, then extended prevention with 10 mg once daily) or apixaban (10 mg twice daily for one week, followed by 5 mg twice daily for six months, then extended prevention with 2.5 mg twice daily) over a lifetime horizon. The model included an initial acute treatment and prevention phase (0–6 months) and an extended prevention phase (6–18 months). Efficacy and safety data were derived from two network meta-analyses. Reference treatment comparators were derived from the EINSTEIN-Pooled study and EINSTEIN-CHOICE trial. Healthcare costs and utility data were derived from published literature. <b><i>Results:</i></b> The rivaroxaban regimen was associated with increased quality-adjusted life years (QALYs) and slightly lower total costs compared with apixaban over a lifetime horizon. Deterministic and probabilistic sensitivity analyses demonstrated that rivaroxaban remained a cost-effective alternative to apixaban over a wide range of parameters. Incremental cost-effectiveness ratio estimates were below the £20,000 per QALY threshold in 74.1% of 2,000 model simulations. Scenario analyses further supported that rivaroxaban is a cost-effective alternative to apixaban. <b><i>Limitations:</i></b> Clinical and safety inputs were derived from network meta-analysis, which are subject to inherent limitations whereby small differences between study designs may severely impact efficacy and safety outcomes. Furthermore, these inputs were based on data from clinical trials, which may not reflect real-world data. <b><i>Conclusions:</i></b> Rivaroxaban was associated with a slightly lower total cost and increased QALYs compared with apixaban for VTE management in the UK over a lifetime horizon.
DOI: 10.6084/m9.figshare.9701795.v3
title: DocGraph Datasets

description: CareSet Journal, formerly, CareSet Labs, was born out of the DocGraph community. In 2010 DocGraph was formed as a movement to create open health data transparency. The efforts of the DocGraph community, guided by Fred Trotter, led to the first national Provider Referral data release by the US government. The original “DocGraph Data” has helped researchers, journalists, and companies around the nation to provide data-backed healthcare solutions.
DOI: 10.6084/m9.figshare.9700406
title: Morphological Measurements KML 2017

description: Various measures of diameter, height, and weight were made for comparison. 50 jellyfish were collected from the Keys Marine Laboratory in Layton, Florida during the Summer of 2017, and maximum bell diameter, resting bell diameter, oral arm diameter, height, wet weight, and dry weight were measured.
DOI: 10.6084/m9.figshare.9700400
title: The effect of heavy metal contamination on humans and animals in the vicinity of a zinc smelting facility

description: The effect of heavy metal contamination on humans and animals in the vicinity of a zinc smelting facility
DOI: 10.6084/m9.figshare.9700400.v1
title: The effect of heavy metal contamination on humans and animals in the vicinity of a zinc smelting facility

description: The effect of heavy metal contamination on humans and animals in the vicinity of a zinc smelting facility
DOI: 10.6084/m9.figshare.9700370
title: KML 2016 Population Transects

description: Size and Abundance of Cassiopea along two transects at the Keys Marine Laboratory in Layton, Florida, in December 2016. Transects were layed by stretching a measuring tape along the bottom, and placing a 1-m quadrat every 5 feet along the measuring tape. Each quadrat was photographed from above and jellyfish measured using ImageJ image analysis software.
DOI: 10.6084/m9.figshare.9699995
title: ACPFLII-COA-STRUCTURE-2

description: ACPFLII-COA-STRUCTURE-2Optimized geometries of intermediates F, G and H and transition states TS5 and 6 starting from structure 2 taken from MD trajectory of acetylated (AcPFL II) topology with CoA in the active site.
DOI: 10.6084/m9.figshare.9700001
title: Supplementary Material for: Risk Factors of Sexual Dysfunction in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study

description: <b><i>Background:</i></b> Hidradenitis suppurativa (HS) has a high impact on quality of life. However, sexual health has scarcely been investigated. <b><i>Objective:</i></b> To describe the frequency of sexual dysfunction (SD) in women and erectile dysfunction (ED) in men with HS and to explore potential risk factors. <b><i>Patients and Methods:</i></b><i></i>We conducted a cross-sectional study using a crowd-sourced online questionnaire spread by the Spanish hidradenitis suppurativa patients’ association (ASENDHI). <b><i>Results:</i></b> In total, 393 participants answered the questionnaire. SD was found in 51% (95% CI 45–57%) of women and ED in 60% (95% CI 49–70%) of men. Factors related to SD were education status, patient’s global assessment for disease activity, numeric rating scale for pain and unpleasant odour and the absence of a stable relationship. Factors related to ED were increasing age, the presence of active lesions in the genital area and the number of areas affected by active lesions. <b><i>Conclusions:</i></b> There is a high prevalence of SD and ED in HS patients. Being in a stable relationship has been a protective factor of SD in women. The results suggest that sexual impairment in HS patients is due, at least in part, to disease activity, symptoms and active lesions.
DOI: 10.6084/m9.figshare.9699995.v1
title: ACPFLII-COA-STRUCTURE-2

description: ACPFLII-COA-STRUCTURE-2Optimized geometries of intermediates F, G and H and transition states TS5 and 6 starting from structure 2 taken from MD trajectory of acetylated (AcPFL II) topology with CoA in the active site.
DOI: 10.6084/m9.figshare.9699938
title: ACPFLII-COA-STRUCTURE-1

description: ACPFLII-COA-STRUCTURE-1Optimized geometries of intermediates F, G and H and transition states TS5 and 6 starting from structure 1 taken from MD trajectory of acetylated (AcPFL II) topology with CoA in the active site.
DOI: 10.6084/m9.figshare.9699932
title: Supplementary Material for: Health-Related Quality of Life, Satisfaction with Care, and Cosmetic Results in Relation to Treatment among Patients with Keratinocyte Cancer in the Head and Neck Area: Results from the PROFILES Registry

description: <b><i>Background:</i></b> Little is known about the impact of keratinocyte cancer (KC) and its treatment on health-related quality of life (HRQoL). <b><i>Objectives:</i></b> The objectives of the present study were (1) to evaluate HRQoL among patients with KC in a population-based setting and compare this with an age- end sex-matched normative population and (2) to compare HRQoL, satisfaction with care, and cosmetic results among patients who underwent conventional excision, Mohs’ micrographic surgery, or radiotherapy. <b><i>Method:</i></b> A random sample of 347 patients diagnosed with cutaneous basal cell or squamous cell carcinoma in the head and neck area between January 1, 2010, and December 31, 2014, were selected from the Netherlands Cancer Registry (NCR) and were invited to complete a questionnaire on HRQoL, satisfaction with care, and cosmetic results. Data were collected within Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship (PROFILES). Outcomes were compared to an age- and sex-matched normative population. <b><i>Results:</i></b> Two hundred fifteen patients with KC returned a completed questionnaire (62% response). Patients with KC reported better global quality of life (79.6 vs. 73.3, <i>p</i> &lt; 0.01) and less pain (<i>p</i> &lt; 0.01) compared to the normative population. No statistically significant differences in HRQoL, satisfaction with care, and cosmetic results were found between patients with KC who underwent conventional excision, Mohs’ micrographic surgery, or radiotherapy. <b><i>Conclusions:</i></b> The impact of KC and its treatment seems relatively low and more positive than negative as patients reported better HRQoL compared to an age- and sex-matched normative population, probably due to adaptation. No statistically significant differences between treatment types were found concerning HRQoL, patient satisfaction, and cosmetic results. This information could be used by healthcare professionals involved in KC care to improve patients’ knowledge about different aspects of the disease as patient’s preference is an important factor for treatment choice.
DOI: 10.6084/m9.figshare.9700001.v1
title: Supplementary Material for: Risk Factors of Sexual Dysfunction in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study

description: <b><i>Background:</i></b> Hidradenitis suppurativa (HS) has a high impact on quality of life. However, sexual health has scarcely been investigated. <b><i>Objective:</i></b> To describe the frequency of sexual dysfunction (SD) in women and erectile dysfunction (ED) in men with HS and to explore potential risk factors. <b><i>Patients and Methods:</i></b><i></i>We conducted a cross-sectional study using a crowd-sourced online questionnaire spread by the Spanish hidradenitis suppurativa patients’ association (ASENDHI). <b><i>Results:</i></b> In total, 393 participants answered the questionnaire. SD was found in 51% (95% CI 45–57%) of women and ED in 60% (95% CI 49–70%) of men. Factors related to SD were education status, patient’s global assessment for disease activity, numeric rating scale for pain and unpleasant odour and the absence of a stable relationship. Factors related to ED were increasing age, the presence of active lesions in the genital area and the number of areas affected by active lesions. <b><i>Conclusions:</i></b> There is a high prevalence of SD and ED in HS patients. Being in a stable relationship has been a protective factor of SD in women. The results suggest that sexual impairment in HS patients is due, at least in part, to disease activity, symptoms and active lesions.
DOI: 10.6084/m9.figshare.9699902
title: ACPFLI-COA-STRUCTURE-1

description: ACPFLI-COA-STRUCTURE-1Optimized geometries of intermediates E, G and H and transition states TS4 and 6 starting from structure 1 taken from MD trajectory of acetylated (AcPFL I) topology with CoA in the active site.
DOI: 10.6084/m9.figshare.9699914
title: ACPFLI-COA-STRUCTURE-2

description: ACPFLI-COA-STRUCTURE-2Optimized geometries of intermediates E, G and H and transition states TS4 and 6 starting from structure 2 taken from MD trajectory of acetylated (AcPFL I) topology with CoA in the active site.
DOI: 10.6084/m9.figshare.9699854
title: Supplementary Material for: Comparison of Hospital Anxiety and Depression Scale (HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in Evaluating Anxiety and Depression in Patients with Psoriatic Arthritis

description: <b><i>Background:</i></b> This study aimed to compare the Hospital Anxiety and Depression Scale (HADS) and the Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in evaluating anxiety and depression in psoriatic arthritis (PsA) patients. <b><i>Methods:</i></b> A total of 70 PsA patients were enrolled. Demographic and clinical characteristics were collected after enrollment. HADS-A and SAS were used to evaluate the anxiety of PsA patients, while HADS-D and SDS were used to evaluate the depression of PsA patients. <b><i>Results:</i></b> Similar results were observed in detecting the rate of anxiety by HADS-A and SAS (27.1 vs. 21.4%, <i>p</i> = 0.424), and there was no difference in classifying the severity of anxiety by HADS-A and SAS (<i>p</i> = 0.347). The Spearman test also disclosed that HADS-A score was positively associated with SAS score (<i>p &lt;</i>0.001). The rates of depression were similar by HADS-D and SDS (27.1 vs. 40.0%; <i>p</i> = 0.108). However, different results were observed in grading the severity of anxiety by HADS-D and SDS (<i>p</i> = 0.009), and no correlation was observed between HADS-D and SDS scores (<i>p</i> = 0.138). The consumption of time for HADS assessment was shorter than that for SAS/SDS assessment (<i>p</i> &lt; 0.001). In addition, a positive correlation of HADS-A score with patients’ global assessment (PGA) (<i>p</i> = 0.022) and fatigue scores (<i>p</i> = 0.028) was discovered, and HADS-D score was positively associated with PGA score (<i>p</i> = 0.019). SAS or SDS score presented less correlation with clinical features of PsA patients, which illuminated that only SAS score was positively associated with duration of psoriasis (<i>p</i> = 0.030). <b><i>Conclusion:</i></b> HADS seems to be a better option for anxiety and depression assessment than SAS/SDS in PsA patients.
DOI: 10.6084/m9.figshare.9699932.v1
title: Supplementary Material for: Health-Related Quality of Life, Satisfaction with Care, and Cosmetic Results in Relation to Treatment among Patients with Keratinocyte Cancer in the Head and Neck Area: Results from the PROFILES Registry

description: <b><i>Background:</i></b> Little is known about the impact of keratinocyte cancer (KC) and its treatment on health-related quality of life (HRQoL). <b><i>Objectives:</i></b> The objectives of the present study were (1) to evaluate HRQoL among patients with KC in a population-based setting and compare this with an age- end sex-matched normative population and (2) to compare HRQoL, satisfaction with care, and cosmetic results among patients who underwent conventional excision, Mohs’ micrographic surgery, or radiotherapy. <b><i>Method:</i></b> A random sample of 347 patients diagnosed with cutaneous basal cell or squamous cell carcinoma in the head and neck area between January 1, 2010, and December 31, 2014, were selected from the Netherlands Cancer Registry (NCR) and were invited to complete a questionnaire on HRQoL, satisfaction with care, and cosmetic results. Data were collected within Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship (PROFILES). Outcomes were compared to an age- and sex-matched normative population. <b><i>Results:</i></b> Two hundred fifteen patients with KC returned a completed questionnaire (62% response). Patients with KC reported better global quality of life (79.6 vs. 73.3, <i>p</i> &lt; 0.01) and less pain (<i>p</i> &lt; 0.01) compared to the normative population. No statistically significant differences in HRQoL, satisfaction with care, and cosmetic results were found between patients with KC who underwent conventional excision, Mohs’ micrographic surgery, or radiotherapy. <b><i>Conclusions:</i></b> The impact of KC and its treatment seems relatively low and more positive than negative as patients reported better HRQoL compared to an age- and sex-matched normative population, probably due to adaptation. No statistically significant differences between treatment types were found concerning HRQoL, patient satisfaction, and cosmetic results. This information could be used by healthcare professionals involved in KC care to improve patients’ knowledge about different aspects of the disease as patient’s preference is an important factor for treatment choice.
DOI: 10.6084/m9.figshare.9699902.v1
title: ACPFLI-COA-STRUCTURE-1

description: ACPFLI-COA-STRUCTURE-1Optimized geometries of intermediates E, G and H and transition states TS4 and 6 starting from structure 1 taken from MD trajectory of acetylated (AcPFL I) topology with CoA in the active site.
DOI: 10.6084/m9.figshare.9699914.v1
title: ACPFLI-COA-STRUCTURE-2

description: ACPFLI-COA-STRUCTURE-2Optimized geometries of intermediates E, G and H and transition states TS4 and 6 starting from structure 2 taken from MD trajectory of acetylated (AcPFL I) topology with CoA in the active site.
DOI: 10.6084/m9.figshare.9699797
title: Synthesis and Anti-inflammatory Evaluation of Some New Pyrazole, Pyrimidine, Pyrazolo[1,5-<i>a</i>]Pyrimidine, Imidazo[1,2-<i>b</i>]Pyrazole and Pyrazolo[5,1-<i>b</i>]Quinazoline Derivatives Containing Indane Moiety

description: A new series of pyrazole, pyrimidine, pyrazolo[1,5-<i>a</i>]pyrimidine, imidazo[1,2-<i>b</i>]pyrazole and pyrazolo[5,1-<i>b</i>]quinazoline derivatives containing indane moiety are prepared by using <i>N</i>-(2,3-dihydro-1<i>H</i>-inden-5-yl)carbonohydrazonoyl dicyanide (<b>2</b>) as starting material to synthetic different heterocyclic compounds (<b>3</b>–<b>11</b>) by the reaction with different bifuncation reagents. Moreover, 4-((2,3-dihydro-1<i>H</i>-inden-5-yl)diazenyl)-1<i>H-</i>pyrazole-3,5-diamine (<b>3</b>) was taken as a precursor to prepare different pyrazolo[1,5-<i>a</i>]pyrimidine derivatives (<b>12</b>–<b>20</b>). The structures of newly synthesized compounds were confirmed on the basis of their IR, 1H NMR, 13C NMR, and mass spectral data. All compounds were evaluated as anti-inflammatory activity by using carrageenan-induced rat paw edema test. In comparison to the standard drug diclofenac sodium, compounds <b>3</b>, <b>7</b>, <b>9</b>, and <b>11</b> exhibited potent activity than standard drug. The compounds <b>2</b> and <b>8</b> showed the most significant anti- anti-inflammatory with 64.83 and 63.95% inhibition of edema.